Format

Send to

Choose Destination
Clin Chim Acta. 2014 Sep 25;436:256-62. doi: 10.1016/j.cca.2014.06.006. Epub 2014 Jun 18.

Development of an ELISA for sPSP94 and utility of the sPSP94/sPSA ratio as a diagnostic indicator to differentiate between benign prostatic hyperplasia and prostate cancer.

Author information

1
Department of Biochemistry & Clinical Nutrition, Seth G.S. Medical College & K.E.M Hospital, Parel, Mumbai, India. Electronic address: d_paralkar@hotmail.com.
2
Division of Structural Biology, National Institute for Research in Reproductive Health, Jehangir Merwanji Street, Parel, Mumbai, India.
3
Department of Molecular Immunodiagnostics, National Institute for Research in Reproductive Health, Jehangir Merwanji Street, Parel, Mumbai, India.
4
Department of Urology, Seth G.S. Medical College & K.E.M Hospital, Parel, Mumbai, India.
5
Department of Genitourinary Oncology, Tata Memorial Hospital, Parel, Mumbai, India.
6
Department of Biochemistry & Clinical Nutrition, Seth G.S. Medical College & K.E.M Hospital, Parel, Mumbai, India.

Abstract

BACKGROUND:

The serum PSA (sPSA) test has low specificity for prostate cancer (PCa), since sPSA also rises in benign prostatic hyperplasia (BPH). Serum PSP94 (sPSP94), a major secreted prostate protein, is indicated as a PCa marker. The potential of sPSP94 and sPSA in conjunction with each other to improve specificity of diagnostic test for PCa needs to be evaluated.

METHODS:

PCa patients (n=33), BPH patients (n=44) and healthy controls (n=50) were recruited. A serum-based sandwich ELISA was developed to measure sPSP94 concentrations. Utility of sPSP94 in improving specificity of sPSA test was evaluated by studying sPSP94/sPSA ratios of study participants.

RESULTS:

Considerable decrease in overlap among sPSP94/sPSA ratio values of BPH and PCa patients was observed, as compared to sPSP94 or sPSA alone. For differentiating between BPH and PCa patients, this ratio had a maximum area under the curve (AUC) of 0.859 (P=0.0132) and had a comparable sensitivity (90.91%) to sPSA with an increased specificity of 70.45%. Further, decision curve analysis (DCA) showed that sPSP94/sPSA ratio had a superior net benefit in identifying PCa, in patients opting for biopsy.

CONCLUSION:

The sPSP94/sPSA ratio can be a better differentiating marker between BPH and PCa, than sPSP94 or sPSA alone.

KEYWORDS:

BPH; ELISA; PCa; sPSP94; sPSP94/sPSA

PMID:
24952364
DOI:
10.1016/j.cca.2014.06.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center